WOCKPHARMA - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 2.5
| Stock Code | WOCKPHARMA | Market Cap | 19,246 Cr. | Current Price | 1,187 ₹ | High / Low | 1,870 ₹ |
| Stock P/E | 95.8 | Book Value | 178 ₹ | Dividend Yield | 0.00 % | ROCE | 4.40 % |
| ROE | -0.53 % | Face Value | 5.00 ₹ | DMA 50 | 1,333 ₹ | DMA 200 | 1,378 ₹ |
| Chg in FII Hold | -0.10 % | Chg in DII Hold | -0.45 % | PAT Qtr | 38.0 Cr. | PAT Prev Qtr | 54.0 Cr. |
| RSI | 32.1 | MACD | -46.8 | Volume | 3,72,143 | Avg Vol 1Wk | 6,16,325 |
| Low price | 1,154 ₹ | High price | 1,870 ₹ | PEG Ratio | 3.96 | Debt to equity | 0.76 |
| 52w Index | 4.60 % | Qtr Profit Var | 273 % | EPS | 11.8 ₹ | Industry PE | 27.2 |
📊 WOCKPHARMA shows weak potential for swing trading. The RSI at 32.1 indicates oversold conditions, which could support a short-term bounce. However, the MACD is sharply negative (-46.8), and the stock is trading below both its 50 DMA (1,333 ₹) and 200 DMA (1,378 ₹), reflecting strong bearish momentum. Valuation is stretched (P/E 95.8 vs industry 27.2, PEG 3.96), and fundamentals are poor with ROCE at 4.4% and ROE negative (-0.53%). Quarterly profits declined (38 Cr. vs 54 Cr.), and institutional activity is negative with both FII (-0.10%) and DII (-0.45%) holdings reduced. Overall, this is a risky swing candidate.
💡 Optimal Entry Price: Around 1,160–1,180 ₹ (near support zone above 1,154 ₹).
📈 Exit Strategy if Holding: Consider exiting near 1,320–1,340 ₹ (close to 50 DMA resistance) unless momentum strengthens further.
Positive
- EPS at 11.8 ₹ provides some valuation support.
- Quarterly profit variation (+273%) shows volatility but potential for recovery.
Limitation
- High valuation compared to peers (P/E 95.8 vs industry 27.2).
- Weak fundamentals (ROCE 4.4%, ROE -0.53%).
- Stock trading below DMA 50 and DMA 200, showing bearish technicals.
- Volumes below weekly average, reflecting reduced trader interest.
Company Negative News
- Quarterly PAT declined (38 Cr. vs 54 Cr.).
- FII holdings reduced (-0.10%) and DII holdings also declined (-0.45%).
- High debt-to-equity ratio (0.76) compared to peers.
Company Positive News
- EPS at 11.8 ₹ supports valuation consistency.
- Profit variation shows potential for sharp rebounds despite volatility.
Industry
- Industry P/E at 27.2 is much lower than WOCKPHARMA’s, highlighting overvaluation.
- Pharma sector remains stable but competitive, with valuations favoring stronger players.
Conclusion
⚖️ WOCKPHARMA is financially weak and technically bearish, making it a highly speculative swing trade. While oversold RSI may trigger a short-term bounce, high valuation, declining profits, and weak fundamentals make it risky. Entry near 1,160–1,180 ₹ with an exit around 1,320–1,340 ₹ is possible, but strict risk management is essential.